Thomas Anthony Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Anthony Anderson has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth De Souza
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California
10 shared publicationsDavid Yeomans
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Medicine, Stanford, California, USA
6 shared publicationsCholawat Pacharinsak
Stanford University School of Medicine Department of Comparative Medicine Stanford, CA
5 shared publications- Micaela Quinn Dugan
University of Michigan Medical School, Ann Arbor
5 shared publications Ellen Wang
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
4 shared publicationsJulia M. Rosenbloom
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (4)
Image-guided focused ultrasound for non-invasive modulation of superficial and deep tissues
- 19 October 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (4)
Open AccessImage-guided focused ultrasound for non-invasive modulation of superficial and deep tissues
- 15 October 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Exploratory Optimization of Focused Ultrasound Parameters for Selective Peripheral Nerve Fiber Inhibition
Was not provided for this article.
- 15 October 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Exploratory Optimization of Focused Ultrasound Parameters for Selective Peripheral Nerve Fiber Inhibition
Was not provided for this article.
- 9 October 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Off Label But on Target: Sevoflurane as a Topical Analgesic
Was not provided for this article.
- 9 October 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Off Label But on Target: Sevoflurane as a Topical Analgesic
Was not provided for this article.
- 29 May 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 143 (3) , 673-675
Comorbidities Associated With Chronic Pain Among Adolescents
- 29 May 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 143 (3) , 673-675
Comorbidities Associated With Chronic Pain Among Adolescents
- Open Access
Noninvasive Diagnostic Ultrasound-Guided Focused Ultrasound Enables Selective, Reversible Inhibition of Peripheral Nociceptive Fibers and Prevents Acute Pain
Background: Acute postoperative pain remains a major clinical therapeutic challenge. Current peripheral nerve blockade (PNB) techniques are effective for some patients but are limited by invasiveness, short duration, reliance on highly trained providers, and off-target motor and sensory effects. Focused ultrasound (FUS) is a novel neuromodulatory technology with the potential to achieve noninvasive, selective, reversible, and prolonged inhibition of peripheral nociceptive fibers to prevent and treat acute pain. We hypothesized that noninvasive transcutaneous targeting of the rat sciatic nerve using co-aligned diagnostic ultrasound (dUS) and FUS transducers could produce selective and reversible inhibition of nociceptive pain behaviors while preserving motor and non-nociceptive sensory functions. Methods: In an in vivo rat hindpaw incisional (HPI) pain model, using a novel, transcutaneous dUS-guided FUS system, the sciatic nerve was located with dUS, and FUS energy was applied to it just prior to hindpaw incision. FUS parameters were iteratively adjusted to achieve reversible, selective inhibition of nociceptive behaviors without changing motor and non-pain sensory behaviors. Animals were randomized into six groups: No Intervention (Control), HPI Only (Disease Control), Sham FUS, FUS Only, FUS+HPI (Intervention), and LA+HPI (Positive Control). Primary outcomes were changes in nociceptive sensory functions, assessed by thermal and mechanical sensitivity. Secondary outcomes were changes in non-nociceptive sensory and motor functions, assessed by hindpaw flexion and extension reflexes. Results: Compared with the HPI Only group, the FUS+HPI group demonstrated (1) significant attenuation of hindpaw thermal hypersensitivity from day 0 - week 5.0 and week 8.0 - 16.0 (p < 0.05–0.001); (2) significant attenuation of mechanical hypersensitivity from day 0 until week 4.0 (p < 0.05–0.001); (3) no significant attenuation of flexion; and (4) no significant attenuation of extension. Conclusions: Transcutaneous dUS-guided FUS enables selective, reversible inhibition of Aδ and C nociceptive fiber mediated behaviors while sparing Aα motor and Aβ sensory behaviors. FUS-induced PNB prevented both acute and persistent pain behaviors. These findings support FUS as a promising noninvasive peripheral nerve blockade strategy for acute pain management.
Open AccessNoninvasive Diagnostic Ultrasound-Guided Focused Ultrasound Enables Selective, Reversible Inhibition of Peripheral Nociceptive Fibers and Prevents Acute Pain
Background: Acute postoperative pain remains a major clinical therapeutic challenge. Current peripheral nerve blockade (PNB) techniques are effective for some patients but are limited by invasiveness, short duration, reliance on highly trained providers, and off-target motor and sensory effects. Focused ultrasound (FUS) is a novel neuromodulatory technology with the potential to achieve noninvasive, selective, reversible, and prolonged inhibition of peripheral nociceptive fibers to prevent and treat acute pain. We hypothesized that noninvasive transcutaneous targeting of the rat sciatic nerve using co-aligned diagnostic ultrasound (dUS) and FUS transducers could produce selective and reversible inhibition of nociceptive pain behaviors while preserving motor and non-nociceptive sensory functions. Methods: In an in vivo rat hindpaw incisional (HPI) pain model, using a novel, transcutaneous dUS-guided FUS system, the sciatic nerve was located with dUS, and FUS energy was applied to it just prior to hindpaw incision. FUS parameters were iteratively adjusted to achieve reversible, selective inhibition of nociceptive behaviors without changing motor and non-pain sensory behaviors. Animals were randomized into six groups: No Intervention (Control), HPI Only (Disease Control), Sham FUS, FUS Only, FUS+HPI (Intervention), and LA+HPI (Positive Control). Primary outcomes were changes in nociceptive sensory functions, assessed by thermal and mechanical sensitivity. Secondary outcomes were changes in non-nociceptive sensory and motor functions, assessed by hindpaw flexion and extension reflexes. Results: Compared with the HPI Only group, the FUS+HPI group demonstrated (1) significant attenuation of hindpaw thermal hypersensitivity from day 0 - week 5.0 and week 8.0 - 16.0 (p < 0.05–0.001); (2) significant attenuation of mechanical hypersensitivity from day 0 until week 4.0 (p < 0.05–0.001); (3) no significant attenuation of flexion; and (4) no significant attenuation of extension. Conclusions: Transcutaneous dUS-guided FUS enables selective, reversible inhibition of Aδ and C nociceptive fiber mediated behaviors while sparing Aα motor and Aβ sensory behaviors. FUS-induced PNB prevented both acute and persistent pain behaviors. These findings support FUS as a promising noninvasive peripheral nerve blockade strategy for acute pain management.
- 16 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Effects of peripheral nerve block adjuvants with and without local anesthetic on ex vivo rodent nerve A-alpha/beta, A-delta, and C fiber activity
Introduction: Preclinical and clinical studies have shown enhanced analgesia when some adjuvant medications are combined with local anesthetics during peripheral nerve (PN) blockade. However, the effects of many adjuvants on individual PN fibers, that is, A-alpha/beta, A-delta, and C, remain poorly characterized. Methods: Using ex vivo rat sciatic nerve electrophysiology, changes in action potential amplitude (AMP) and area under the curve (AUC) for A-alpha/beta, A-delta, and C fibers were used to determine the half-maximal effective concentrations (EC50) for four adjuvants (dexmedetomidine, magnesium, epinephrine, ketorolac) with and without bupivacaine. At a clinically relevant “high” concentration, each adjuvant’s effects on AMP, AUC, and latency to 100% peak AMP were evaluated with and without bupivacaine, then statistically compared with control (no drug) and bupivacaine-alone conditions. Results: EC50s for the four adjuvants were determined for some fibers: dexmedetomidine (A-alpha/beta, A-delta, C fibers), magnesium (A-delta fibers), epinephrine (C fibers), and ketorolac (A-alpha/beta and A-delta fibers). At the high concentrations, adjuvants alone produced few significant differences when compared with control, and adjuvants with bupivacaine produced few significant differences when compared with bupivacaine alone. Discussion: Using ex vivo electrophysiology, we identified EC50s of dexmedetomidine, magnesium, epinephrine, and ketorolac for A-alpha/beta, A-delta, and/or C fiber AMP, demonstrating that these adjuvants have direct effects on PN fibers. Future investigations may benefit by testing different concentrations of adjuvants and bupivacaine in an in vivo model incorporating a broader range of time points.
- 16 January 2026
- Published by BMJ in Regional Anesthesia & Pain Medicine
Effects of peripheral nerve block adjuvants with and without local anesthetic on ex vivo rodent nerve A-alpha/beta, A-delta, and C fiber activity
Introduction: Preclinical and clinical studies have shown enhanced analgesia when some adjuvant medications are combined with local anesthetics during peripheral nerve (PN) blockade. However, the effects of many adjuvants on individual PN fibers, that is, A-alpha/beta, A-delta, and C, remain poorly characterized. Methods: Using ex vivo rat sciatic nerve electrophysiology, changes in action potential amplitude (AMP) and area under the curve (AUC) for A-alpha/beta, A-delta, and C fibers were used to determine the half-maximal effective concentrations (EC50) for four adjuvants (dexmedetomidine, magnesium, epinephrine, ketorolac) with and without bupivacaine. At a clinically relevant “high” concentration, each adjuvant’s effects on AMP, AUC, and latency to 100% peak AMP were evaluated with and without bupivacaine, then statistically compared with control (no drug) and bupivacaine-alone conditions. Results: EC50s for the four adjuvants were determined for some fibers: dexmedetomidine (A-alpha/beta, A-delta, C fibers), magnesium (A-delta fibers), epinephrine (C fibers), and ketorolac (A-alpha/beta and A-delta fibers). At the high concentrations, adjuvants alone produced few significant differences when compared with control, and adjuvants with bupivacaine produced few significant differences when compared with bupivacaine alone. Discussion: Using ex vivo electrophysiology, we identified EC50s of dexmedetomidine, magnesium, epinephrine, and ketorolac for A-alpha/beta, A-delta, and/or C fiber AMP, demonstrating that these adjuvants have direct effects on PN fibers. Future investigations may benefit by testing different concentrations of adjuvants and bupivacaine in an in vivo model incorporating a broader range of time points.
- 24 September 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (9) , e70079
Focused Ultrasound‐Induced Peripheral Nerve Blockade: Duration of Changes to Thermal Withdrawal Latency and Nerve Structure After Focused Ultrasound Application to the Sciatic Nerve in a Rat Model of Acute Pain
Focused ultrasound (FUS) holds potential to inhibit peripheral nerves to manage pain. We previously found FUS parameters resulting in changes to nerve structure and reversible increased mechanical withdrawal threshold as well as reversible inhibition of motor and non‐pain sensory fibers. However, as behaviors were only followed for 4 weeks and structure for 2 weeks, the duration of increased thermal withdrawal latency and changes to nerve structure were undetermined. We investigated the duration of increased thermal withdrawal latency and nerve structure alterations after FUS application in an acute pain model. FUS was applied directly to the rat sciatic nerve prior to hindpaw (HP) incision; animal behaviors (thermal and mechanical nociceptive thresholds, HP extension and flexion) were assessed for 12 weeks and nerve structure was assessed for 28 weeks. The primary outcome was the change in HP thermal withdrawal latency. Secondary outcomes were the changes to sciatic nerve structure and HP mechanical withdrawal threshold, extension, and flexion. Compared with controls, after FUS application, animals had increased thermal nociceptive thresholds until week 9, increased mechanical nociceptive thresholds until week 2, decreased HP motor response until week 3.5, and decreased HP plantar sensation until week 4. Nerve ultrastructure changes may have persisted until week 24. In this new longer‐term follow‐up study, after invasive FUS application to the sciatic nerve in a rodent model of acute incisional pain, we determined the duration of changes to thermal hyperalgesia, mechanical hyperalgesia, motor, and non‐pain sensory responses, and changes to nerve structure.
- 24 September 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (9) , e70079
Focused Ultrasound‐Induced Peripheral Nerve Blockade: Duration of Changes to Thermal Withdrawal Latency and Nerve Structure After Focused Ultrasound Application to the Sciatic Nerve in a Rat Model of Acute Pain
Focused ultrasound (FUS) holds potential to inhibit peripheral nerves to manage pain. We previously found FUS parameters resulting in changes to nerve structure and reversible increased mechanical withdrawal threshold as well as reversible inhibition of motor and non‐pain sensory fibers. However, as behaviors were only followed for 4 weeks and structure for 2 weeks, the duration of increased thermal withdrawal latency and changes to nerve structure were undetermined. We investigated the duration of increased thermal withdrawal latency and nerve structure alterations after FUS application in an acute pain model. FUS was applied directly to the rat sciatic nerve prior to hindpaw (HP) incision; animal behaviors (thermal and mechanical nociceptive thresholds, HP extension and flexion) were assessed for 12 weeks and nerve structure was assessed for 28 weeks. The primary outcome was the change in HP thermal withdrawal latency. Secondary outcomes were the changes to sciatic nerve structure and HP mechanical withdrawal threshold, extension, and flexion. Compared with controls, after FUS application, animals had increased thermal nociceptive thresholds until week 9, increased mechanical nociceptive thresholds until week 2, decreased HP motor response until week 3.5, and decreased HP plantar sensation until week 4. Nerve ultrastructure changes may have persisted until week 24. In this new longer‐term follow‐up study, after invasive FUS application to the sciatic nerve in a rodent model of acute incisional pain, we determined the duration of changes to thermal hyperalgesia, mechanical hyperalgesia, motor, and non‐pain sensory responses, and changes to nerve structure.
- 7 August 2025
- Published by Wiley in Current Protocols
- Vol. 5 (8) , e70190
Whole Nerve Electrophysiology and Analyses of A‐alpha/beta, A‐delta, and C Fiber Action Potentials
Ex vivo whole peripheral nerve electrophysiology provides a powerful tool for evaluating the effects of current and potential clinical treatments on nerve impulse transmission. It allows quantitative assessment of nerve conduction through compound action potential (AP) recordings, which can be correlated with sensory and motor changes. However, existing literature lacks a comprehensive methodology for isolating and analyzing APs from individual nerve fiber subtypes (e.g., A‐alpha/beta, A‐delta, and C fibers). This article details the optimal setup conditions and nerve stimulator parameters required to capture APs from specific nerve fibers reliably and provides a detailed and systematic approach for their analysis. © 2025 Wiley Periodicals LLC.Basic Protocol 1: Setup conditions for obtaining individual nerve fiber action potentialsBasic Protocol 2: Nerve handling and parameters for optimal nerve healthBasic Protocol 3: Nerve stimulation to obtain nerve fiber action potentialsSupport Protocol 1: Parameters for A‐alpha/beta fiber stimulation and recordingSupport Protocol 2: Parameters for A‐delta and C fiber stimulation and recordingBasic Protocol 4: Quantitative analysis of nerve fiber action potentialsSupport Protocol 3: A‐alpha/beta fiber analysisSupport Protocol 4: A‐delta fiber analysisSupport Protocol 5: C fiber analysis
- 7 August 2025
- Published by Wiley in Current Protocols
- Vol. 5 (8) , e70190
Whole Nerve Electrophysiology and Analyses of A‐alpha/beta, A‐delta, and C Fiber Action Potentials
Ex vivo whole peripheral nerve electrophysiology provides a powerful tool for evaluating the effects of current and potential clinical treatments on nerve impulse transmission. It allows quantitative assessment of nerve conduction through compound action potential (AP) recordings, which can be correlated with sensory and motor changes. However, existing literature lacks a comprehensive methodology for isolating and analyzing APs from individual nerve fiber subtypes (e.g., A‐alpha/beta, A‐delta, and C fibers). This article details the optimal setup conditions and nerve stimulator parameters required to capture APs from specific nerve fibers reliably and provides a detailed and systematic approach for their analysis. © 2025 Wiley Periodicals LLC.Basic Protocol 1: Setup conditions for obtaining individual nerve fiber action potentialsBasic Protocol 2: Nerve handling and parameters for optimal nerve healthBasic Protocol 3: Nerve stimulation to obtain nerve fiber action potentialsSupport Protocol 1: Parameters for A‐alpha/beta fiber stimulation and recordingSupport Protocol 2: Parameters for A‐delta and C fiber stimulation and recordingBasic Protocol 4: Quantitative analysis of nerve fiber action potentialsSupport Protocol 3: A‐alpha/beta fiber analysisSupport Protocol 4: A‐delta fiber analysisSupport Protocol 5: C fiber analysis